Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses
| dc.citation.articleNumber | 100128 | en_US |
| dc.citation.journalTitle | One Health | en_US |
| dc.citation.volumeNumber | 9 | en_US |
| dc.contributor.author | Amirian, E. Susan | en_US |
| dc.contributor.author | Levy, Julie K. | en_US |
| dc.contributor.org | Texas Policy Lab | en_US |
| dc.contributor.publisher | Elsevier | en_US |
| dc.date.accessioned | 2020-04-24T15:49:15Z | en_US |
| dc.date.available | 2020-04-24T15:49:15Z | en_US |
| dc.date.issued | 2020 | en_US |
| dc.description.abstract | Recent international epidemics of coronavirus-associated illnesses underscore the urgent medical and public health need for vaccine development and regulatory body approved therapies. In particular, the current coronavirus disease 2019 (COVID-19) pandemic has quickly intensified interest in developing treatment options to mitigate impact on human life. Remdesivir (GS-5734™) is a broad-spectrum antiviral drug that is now being tested as a potential treatment for COVID-19 in international, multi-site clinical trials. Currently available evidence about the antiviral effects of remdesivir against coronaviruses is primarily based on in vitro and in vivo studies (including some on a chemically related compound, GS-441524™), which have demonstrated largely favorable findings. As the pandemic progresses, information from human compassionate use cases will continue to accumulate before the clinical trials are concluded. It is imperative for public health practitioners and the One Health community to stay up to date on the most promising potential therapeutic options that are under investigation. Thus, the purpose of this review is to synthesize the knowledge to date about remdesivir as a therapeutic option for coronaviruses, with a special focus on information relevant to the One Health community. | en_US |
| dc.identifier.citation | Amirian, E. Susan and Levy, Julie K.. "Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses." <i>One Health,</i> 9, (2020) https://doi.org/10.1016/j.onehlt.2020.100128. | en_US |
| dc.identifier.doi | https://doi.org/10.1016/j.onehlt.2020.100128 | en_US |
| dc.identifier.uri | https://hdl.handle.net/1911/108372 | en_US |
| dc.language.iso | eng | en_US |
| dc.rights | This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/) | en_US |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | en_US |
| dc.subject.keyword | Remdesivir | en_US |
| dc.subject.keyword | GS-5734 | en_US |
| dc.subject.keyword | Coronavirus | en_US |
| dc.subject.keyword | COVID-19 | en_US |
| dc.subject.keyword | SARS-CoV-2 | en_US |
| dc.subject.keyword | Compassionate use | en_US |
| dc.title | Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses | en_US |
| dc.type | Journal article | en_US |
| dc.type.dcmi | Text | en_US |
| dc.type.publication | publisher version | en_US |